NCT05217355View on ClinicalTrials.gov

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Glabellar Frown Lines
Interventions
DRUG

MBA-P01 (Botulinum toxin A)

MBA-P01 will be injected into the Glabellar line

DRUG

Placebo

Placebo will be injected into the Glabellar line

Trial Locations (1)

156-755

Chung-And Univ. Hospital, Seoul

All Listed Sponsors
lead

Medytox Korea

INDUSTRY

NCT05217355 - A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter